CYP19A1 and breast cancer: A recent In vitro study demonstrated that SLC1A5 is upregulated in breast cancer cells resistant to endocrine therapy and that SLC1A5 inhibition decreased cell proliferation in aromatase inhibitors resistant breast cancer cells [31].